| Chad Thompson, | |
|
3330 Nw 56th St, Suite 206, Oklahoma City, OK 73112-4479 | |
| (405) 945-4740 | |
| (405) 945-4751 |
| Full Name | Chad Thompson |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 19 Years |
| Location | 3330 Nw 56th St, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447452560 | NPI | - | NPPES |
| 200246380A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 24966 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Integris Southwest Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ibmc Er Physicians | 6709963085 | 12 |
News Archive
Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.
More than half of older women with early stage breast cancer received more radiation therapy than what might be medically necessary, adding additional treatment and health care costs, according to a study led by Duke Cancer Institute researchers.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.
› Verified 1 days ago
| Entity Name | Ibmc Er Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295839280 PECOS PAC ID: 6709963085 Enrollment ID: O20080410000682 |
News Archive
Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.
More than half of older women with early stage breast cancer received more radiation therapy than what might be medically necessary, adding additional treatment and health care costs, according to a study led by Duke Cancer Institute researchers.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chad Thompson, 3330 Nw 56th St, Suite 206, Oklahoma City, OK 73112-4479 Ph: (405) 945-4740 | Chad Thompson, 3330 Nw 56th St, Suite 206, Oklahoma City, OK 73112-4479 Ph: (405) 945-4740 |
News Archive
Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.
More than half of older women with early stage breast cancer received more radiation therapy than what might be medically necessary, adding additional treatment and health care costs, according to a study led by Duke Cancer Institute researchers.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.
› Verified 1 days ago
Dr. Jennifer Kathleen Hinkle, MD Radiology Medicare: Medicare Enrolled Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-456-2589 | |
Dr. Bryan Lee Vanzandt, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4625 S Western Ave, Oklahoma City, OK 73109 Phone: 405-632-2323 Fax: 405-631-9315 | |
Charles Eric Eckman, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 14101 Parkway Commons, Oklahoma City, OK 73134 Phone: 405-749-6277 | |
Robert K Gelczer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St., Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
Vikas Vij, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
William G Phillips, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2224 Nw 50th St, Suite 276w, Oklahoma City, OK 73112 Phone: 405-858-2350 | |
Ronald Ray Magee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5224 E I 240 Service Rd Ste 303, Oklahoma City, OK 73135 Phone: 405-608-3800 Fax: 405-628-6477 |